GlassScriptPhysician profile
Muhammad Ahsan
NPI 1063967057
$3,305.63
in general payments reported to CMS, 2019-2025
20 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.61 · 2021: $66.42 · 2022: $525 · 2023: $1,505 · 2024: $701 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Travel and Lodging: $462 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.88 |
| Travel and Lodging | $461.66 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $914.45 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $381.33 | 2024-2025 | Impella |
| Medtronic, INC. | $365.44 | 2022-2025 | Azure Xt Dr Mri Surescan, Linq II |
| Abbott Laboratories | $362.69 | 2022-2025 | Durata |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.84 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $216.43 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $117.28 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $110.86 | 2023-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.78 | 2020-2022 | |
| Teleflex LLC | $101.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.15 | 2023-2024 | |
| Artivion, INC. | $90.91 | 2024 | Amds-Ascyrus Medical |
| Alnylam Pharmaceuticals INC. | $61.39 | 2023-2025 | Amvuttra |
| Shockwave Medical, INC | $37.53 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $25.57 | 2024 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.68 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $22.65 | 2023 | Andexxa |
| Inspire Medical Systems, INC. | $21.08 | 2025 | Inspire |
| Scpharmaceuticals INC. | $14.24 | 2024 | |
| Pfizer INC. | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.